0.93 USD
▼+0.08-0.55%
盘后 0.92 -1.49%
2026-08-03
市值
$63.51M
市盈率
—
EPS
-0.67
股息率
—
52 周区间
0.76 – 3.31
成交量
646.83K
Beta
1.44
目标价
5.21
52W 低 0.7652W 高 3.31
价格走势
公司简介
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR...